NoteIntestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: A study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10
References (10)
Kinetic impact of presystemic intestinal metabolism on drug absorption: experiment and data analysis for the prediction of in vivo absorption from in vitro data
Drug Metab. Pharmacokinet.
(2002)Assessment of presystemic and systemic intestinal availability of orally administered drugs using in vitro and in vivo data in humans: intestinal sulfation metabolism impacts presystemic availability much more than systemic availability of salbutamol SULT1A3 substrate
J. Pharm. Sci.
(2008)- et al.
Intestinal transport and metabolism of glucose-conjugated kyotorphin and cyclic kyotorphin: metabolic degradation is crucial to intestinal absorption of peptide drugs
Biochim. Biophys. Acta
(2000) - et al.
Physiological parameters in laboratory animals and humans
Pharm. Res.
(1993) - et al.
Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance
Drug Metab. Dispos.
(2002)
There are more references available in the full text version of this article.
Cited by (85)
Factors Affecting Drug Absorption and Disposition
2023, Pharmaceutics: Basic Principles and Application to Pharmacy Practice, Second EditionPharmacogenetics/Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters
2022, Comprehensive PharmacologyInteraction between apigenin and sodium deoxycholate with raloxifene: A potential risk for clinical practice
2021, European Journal of Pharmaceutical SciencesCitation Excerpt :After intravenous application raloxifene concentrations were measurable in all four groups, though significant deviation in each time point was detected. This is in correlation with previous research where significant interindividual variability in raloxifene pharmacokinetics was obtained (Kosaka et al., 2011; Lindstrom et al., 1984; Mizuma, 2009; Morello et al., 2003; Jha et al., 2011; Snyder et al., 2000). Pharmacokinetic interactions between API and NaDC, used in pretreatment, and raloxifene were evident after intravenous application of raloxifene.
Biopharmaceutical properties of natural products
2021, Mitochondrial Physiology and Vegetal Molecules: Therapeutic Potential of Natural Compounds on Mitochondrial HealthSelf-assembled lecithin-chitosan nanoparticles improve the oral bioavailability and alter the pharmacokinetics of raloxifene
2020, International Journal of Pharmaceutics
Copyright © 2009 Elsevier B.V. All rights reserved.